A field team can see what was prescribed. What happens after that, in most of the retail channel, is a black box. The prescription either becomes a filled prescription or it does not, and the reasons are invisible from outside the pharmacy.
What is visible from our side
- Written to filled conversion. Of the prescriptions transmitted to us for a product, how many were actually dispensed.
- Time to therapy. Days between transmission and the patient having the medication, which is where prior authorization friction shows up as a number rather than an anecdote.
- Refill persistence. How many patients are still on therapy at 90 and 180 days.
- Abandonment with a reason attached. Cost, coverage denial, or the patient declining. These are three different problems and only one of them is a pricing problem.
Why abandonment reason is the number worth having
An abandoned prescription and an adherent patient look identical in prescribing data. Separating them changes what you do next. If patients are abandoning on cost, the copay program is not reaching the counter. If they are abandoning on coverage, the issue is formulary position or step therapy criteria. If they are declining the therapy, that is a conversation for the prescriber rather than a market access problem.
What we need from you for any of it to work
- The product stocked ahead of demand, so the first prescription does not turn into a special order and a three-day delay.
- Copay cards, vouchers, bridge and patient assistance details, so we can apply them automatically rather than asking a patient to go find them.
- The coverage landscape as you understand it, including which plans impose step therapy and what satisfies it, so our team is not learning it one denial at a time.
Reporting to a manufacturer partner is aggregated and de-identified. We do not sell patient data, we do not accept payment for referrals, and we do not steer a prescriber toward a product. The prescriber picks the therapy. Our work starts after that decision.
The commitment underneath the data
Reporting is only useful if the underlying behavior is consistent. When a prescriber in our network writes your product, we stock it, we work the prior authorization rather than reversing to cash, we apply your access programs at the point of dispense, and we contact the patient before the refill lapses. The data is a description of that, not a substitute for it.